Common genetic variants do not impact clinical prediction of methotrexate treatment outcomes in early rheumatoid arthritis.

Journal: Journal of internal medicine
Published Date: Apr 6, 2025

Abstract

BACKGROUND: Methotrexate (MTX) is the mainstay initial treatment of rheumatoid arthritis (RA), but individual response varies and remains difficult to predict. The role of genetics remains unclear, but studies suggest its importance.

Authors

  • Anton Öberg Sysojev
    Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Bénédicte Delcoigne
    Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Thomas Frisell
    Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Lars Alfredsson
    Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Lars Klareskog
    Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Saedis Saevarsdottir
    Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Magnus Boman
    Karolinska Institutet, Department of Medicine Solna, Division of Clinical Epidemiology, Stockholm, Sweden.
  • Leonid Padyukov
    Division of Rheumatology, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, 17177, Stockholm, Sweden.
  • Johan Askling
    Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Helga Westerlind
    Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

Keywords

External Resources

Popular Topics
Recent Journals